Dolutegravir

WHO warns of growing resistance to GSK's HIV drug
Reuters
Wed, 03/6/24 - 11:46 am
GSK
HIV
Dolutegravir
drug resistance
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
Mon, 07/12/21 - 11:08 am
patents
patent cliff
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Revlimid
Pfizer
Eliquis
Regeneron
Eylea
JNJ
Stelara
Opdivo
GSK
Dolutegravir
Ibrance
Januvia
Eli Lilly
Trulicity
Novo Nordisk
Victoza
Amgen
Prolia
Xgeva
Novartis
Cosentyx
Takeda
Entyvio
Glaxo needs long-acting HIV gamble to pay off
EP Vantage
Thu, 06/24/21 - 10:57 am
GSK
HIV
Dolutegravir
patents
GSK's ViiV seeks marketing license for baby-friendly HIV pill
Reuters
Sun, 12/15/19 - 12:23 am
GSK
HIV
Dolutegravir
pediatric
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
Pharmaceutical Business Review
Thu, 04/4/19 - 11:58 am
ViiV Healthcare
Dolutegravir
rilpivirine
JNJ
Janssen
HIV
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Yahoo/Reuters
Wed, 06/20/18 - 09:28 am
GSK
Gilead Sciences
HIV
AIDS
Dolutegravir
lamivudine
Biktarvy
ViiV Healthcare reports positive results for late-stage HIV trials
Marketwatch
Thu, 06/14/18 - 09:19 am
ViiV Healthcare
GSK
Pfizer
Shionogi
HIV
clinical trials
Dolutegravir
lamivudine
Regulators flag possible birth defect link to GSK's HIV drug
Yahoo/Reuters
Fri, 05/18/18 - 09:27 pm
GSK
HIV
Dolutegravir
birth defects
EMA
FDA
GSK and Gilead go head to head as HIV drugs enter new phase
Reuters
Fri, 11/3/17 - 11:01 am
GSK
Gilead Sciences
HIV
Dolutegravir
bictegravir
Gilead needs to best Glaxo with bictegravir
EP Vantage
Thu, 05/18/17 - 12:14 am
Gilead Sciences
GSK
bictegravir
Dolutegravir
HIV
Gilead challenges GSK with strong HIV drug data
Yahoo/Reuters
Tue, 02/14/17 - 09:28 am
Gilead Sciences
GSK
HIV
bictegravir
Dolutegravir
GlaxoSmithKline and Gilead to face off at HIV meeting next week
Yahoo/Reuters
Thu, 02/9/17 - 09:44 am
GSK
Gilead Sciences
HIV
bictegravir
Dolutegravir
ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment
Yahoo
Tue, 08/16/16 - 11:14 am
ViiV Healthcare
HIV
Dolutegravir
HIV-1
lamivudine
ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV
Yahoo
Fri, 06/10/16 - 10:06 am
ViiV Healthcare
HIV
FDA
pediatric
Dolutegravir
ViiV Healthcare files new drug application for three-drug HIV pill with US FDA
Pharmaceutical-Technology
Wed, 10/23/13 - 09:57 am
HIV
FDA
ViiV Healthcare
Dolutegravir
abacavir
lamivudine
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
Yahoo
Fri, 09/13/13 - 08:30 am
Dolutegravir
ViiV Healthcare
Darunavir
HIV-1
ING114915
Glaxo Wins U.S. FDA Approval for New Daily HIV Therapy
Bloomberg
Mon, 08/12/13 - 05:26 pm
GSK
FDA
HIV
ViiV Healthcare
Tivicay
Dolutegravir
Innovations In HIV: Johnson & Johnson, Glaxo Vs. Gilead
Seeking Alpha
Mon, 07/22/13 - 10:26 am
HIV
Atripla
JNJ
Pfizer
GSK
Gilead
Dolutegravir
Edurant
China
TMC310911
ViiV Healthcare Partnership Anticipates New HIV Treatment Approval
Seeking Alpha
Sat, 06/22/13 - 10:09 am
ViiV Healthcare
GSK
Pfizer
Shionogi
Dolutegravir
HIV
2013 FDA Drug Approval Calendar
TheStreet.com
Tue, 05/21/13 - 12:05 pm
drug approvals
GSK
Dolutegravir
Trametenib
Auxilium
Xiaflex
Delcath
Melblez
Seattle Genetics
Adcetris
Antares
Otrexup
Amag Pharmaceuticals
Feraheme
Cubist Pharmaceuticals
Entereg
Gilead
sofosbuvir
Amarin
Vascepa
Merck
suvorexant
Valeant Pharmaceuticals
efinaconazole
Depomed
Sefelsa
Zogenix
Zohydro
dabrafenib
tivozanib
Aveo Pharmaceuticals

Pages